Karyopharm Therapeutics(KPTI)
Focus: Karyopharm is a public-stage biotechnology company focused on small-molecule oncology and hematology therapeutics, centered on its lead platform Selinexor with applications across multiple cancer indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
20+9 this month
Growing — net +9 jobs in 30d
26 jobs added vs 17 removed. Steady team buildout.
Should You Work at Karyopharm Therapeutics?
AI assessmentBest fit for pipeline-focused scientists and early-stage clinical developers willing to accept near-term financial uncertainty for Phase 3 catalyst upside.
Why Work Here
- Selinexor has Phase 3 programs in endometrial cancer and myelofibrosis, providing near-term clinical catalysts and potential commercial upside
- 95% R&D intensity signals deep commitment to innovation-driven pipeline development across 30 programs spanning Phase 1–3
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$146M
Key Products
Selinexor
Stable
Peak
Lead asset with 16 active programs across Phase 1–3; endometrial cancer and myelofibrosis Phase 3 programs represent highest value catalysts.
Pipeline & Clinical Trials
Help build intelligence for Karyopharm Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.